DGX DCF Model
| Dec'19 Actual | Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Estimate | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Terminal | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 7,726.0 2.6% | 9,437.0 22.1% | 10,788.0 14.3% | 9,883.0 (8.4%) | 9,252.0 (6.4%) | 9,829.7 6.2% | 10,708.0 8.9% | 11,130.9 3.9% | 11,684.9 5.0% | 12,056.0 3.2% | 12,435.3 3.1% | 12,822.9 3.1% | 13,218.9 3.1% | 13,623.2 3.1% | 14,035.9 3.0% | 14,456.9 3.0% |
% margin | 1,231.0 15.9% | 1,971.0 20.9% | 2,381.0 22.1% | 1,428.0 14.4% | 1,262.0 13.6% | 1,797.8 18.3% | 1,958.5 18.3% | 2,035.8 18.3% | 2,137.1 18.3% | 2,205.0 18.3% | 2,274.4 18.3% | 2,345.3 18.3% | 2,417.7 18.3% | 2,491.7 18.3% | 2,567.1 18.3% | 2,644.2 18.3% |
NOPAT % effective tax rate | 948.4 12.3% | 1,489.8 15.8% | 1,834.1 17.0% | 1,122.7 11.4% | 985.0 10.6% | 1,403.3 14.3% | 1,528.7 14.3% | 1,589.0 14.3% | 1,668.1 14.3% | 1,721.1 14.3% | 1,775.2 14.3% | 1,830.6 14.3% | 1,887.1 14.3% | 1,944.8 14.3% | 2,003.7 14.3% | 2,063.8 14.3% |
% of revenue | 329.0 4.3% | 361.0 3.8% | 408.0 3.8% | 437.0 4.4% | 439.0 4.7% | 424.3 4.3% | 462.2 4.3% | 480.4 4.3% | 504.3 4.3% | 520.4 4.3% | 536.7 4.3% | 553.5 4.3% | 570.6 4.3% | 588.0 4.3% | 605.8 4.3% | 624.0 4.3% |
% of revenue | (400.0) (5.2%) | (418.0) (4.4%) | (403.0) (3.7%) | (404.0) (4.1%) | (408.0) (4.4%) | (400.8) (4.1%) | (436.6) (4.1%) | (453.9) (4.1%) | (476.5) (4.1%) | (491.6) (4.1%) | (507.1) (4.1%) | (522.9) (4.1%) | (539.0) (4.1%) | (555.5) (4.1%) | (572.4) (4.1%) | (589.5) (4.1%) |
% of revenue | 35.0 0.5% | 22.0 0.2% | 87.0 0.8% | 119.0 1.2% | (145.0) (1.6%) | 14.5 0.1% | 15.8 0.1% | 16.4 0.1% | 17.3 0.1% | 17.8 0.1% | 18.4 0.1% | 18.9 0.1% | 19.5 0.1% | 20.1 0.1% | 20.7 0.1% | 21.4 0.1% |
Free Cash Flow to Firm (FCFF) % of revenue | 912.4 11.8% | 1,454.8 15.4% | 1,926.1 17.9% | 1,274.7 12.9% | 871.0 9.4% | 1,441.2 14.7% | 1,570.0 14.7% | 1,632.0 14.7% | 1,713.2 14.7% | 1,767.6 14.7% | 1,823.3 14.7% | 1,880.1 14.7% | 1,938.2 14.7% | 1,997.4 14.7% | 2,057.9 14.7% | 2,119.7 14.7% |
% of FCFF used in calculation | 100.0% | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||||||
Discount period | 0.50 | 1.50 | 2.50 | 3.50 | 4.50 | 5.50 | 6.50 | 7.50 | 8.50 | |||||||
Discount factor | 0.97 | 0.92 | 0.87 | 0.82 | 0.78 | 0.73 | 0.69 | 0.65 | 0.62 | |||||||
Discounted FCFF (DFCFF) | 1,267.1 | 1,499.6 | 1,487.9 | 1,450.9 | 1,414.4 | 1,378.5 | 1,343.1 | 1,308.3 | 1,274.0 |
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
DGX DCF Value
DCF Value Calculation
Equity Value Bridge
DGX DCF Financials
DGX DCF sensitivity
Explore more intrinsic value tools hub for DGX
FAQ
What is Quest Diagnostics Incorporated DCF (discounted cash flow) valuation?
As of Mar 03, 2025, Quest Diagnostics Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at $331.1. This suggests it may be undervalued by 87.1% compared to its current price of around $177.0, using a WACC of 5.8% and growth rates of 3.0%.
What is Quest Diagnostics Incorporated WACC?
As of Mar 03, 2025, Quest Diagnostics Incorporated's Weighted Average Cost of Capital (WACC) is approximately 5.8%.
What is Quest Diagnostics Incorporated Enterprise Value?
As of Mar 03, 2025, Quest Diagnostics Incorporated's Enterprise Value (EV) is approximately $41.4B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.